Historical Valuation
Beam Therapeutics Inc (BEAM) is now in the Fair zone, suggesting that its current forward PS ratio of 44.02 is considered Fairly compared with the five-year average of -10.51. The fair price of Beam Therapeutics Inc (BEAM) is between 22.71 to 29.11 according to relative valuation methord.
Relative Value
Fair Zone
22.71-29.11
Current Price：27.96
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Beam Therapeutics Inc (BEAM) has a current Price-to-Book (P/B) ratio of 2.77. Compared to its 3-year average P/B ratio of 2.51 , the current P/B ratio is approximately 10.55% higher. Relative to its 5-year average P/B ratio of 4.90, the current P/B ratio is about -43.49% higher. Beam Therapeutics Inc (BEAM) has a Forward Free Cash Flow (FCF) yield of approximately -13.15%. Compared to its 3-year average FCF yield of -12.73%, the current FCF yield is approximately 3.35% lower. Relative to its 5-year average FCF yield of -7.68% , the current FCF yield is about 71.37% lower.
P/B
Median3y
2.51
Median5y
4.90
FCF Yield
Median3y
-12.73
Median5y
-7.68
Competitors Valuation Multiple
AI Analysis for BEAM
The average P/S ratio for BEAM competitors is 60.07, providing a benchmark for relative valuation. Beam Therapeutics Inc Corp (BEAM.O) exhibits a P/S ratio of 44.02, which is -26.72% above the industry average. Given its robust revenue growth of -32.03%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for BEAM
1Y
3Y
5Y
Market capitalization of BEAM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BEAM in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BEAM currently overvalued or undervalued?
Beam Therapeutics Inc (BEAM) is now in the Fair zone, suggesting that its current forward PS ratio of 44.02 is considered Fairly compared with the five-year average of -10.51. The fair price of Beam Therapeutics Inc (BEAM) is between 22.71 to 29.11 according to relative valuation methord.
What is Beam Therapeutics Inc (BEAM) fair value?
BEAM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Beam Therapeutics Inc (BEAM) is between 22.71 to 29.11 according to relative valuation methord.
How does BEAM's valuation metrics compare to the industry average?
The average P/S ratio for BEAM's competitors is 60.07, providing a benchmark for relative valuation. Beam Therapeutics Inc Corp (BEAM) exhibits a P/S ratio of 44.02, which is -26.72% above the industry average. Given its robust revenue growth of -32.03%, this premium appears unsustainable.
What is the current P/B ratio for Beam Therapeutics Inc (BEAM) as of Jan 09 2026?
As of Jan 09 2026, Beam Therapeutics Inc (BEAM) has a P/B ratio of 2.77. This indicates that the market values BEAM at 2.77 times its book value.
What is the current FCF Yield for Beam Therapeutics Inc (BEAM) as of Jan 09 2026?
As of Jan 09 2026, Beam Therapeutics Inc (BEAM) has a FCF Yield of -13.15%. This means that for every dollar of Beam Therapeutics Inc’s market capitalization, the company generates -13.15 cents in free cash flow.
What is the current Forward P/E ratio for Beam Therapeutics Inc (BEAM) as of Jan 09 2026?
As of Jan 09 2026, Beam Therapeutics Inc (BEAM) has a Forward P/E ratio of -5.84. This means the market is willing to pay $-5.84 for every dollar of Beam Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Beam Therapeutics Inc (BEAM) as of Jan 09 2026?
As of Jan 09 2026, Beam Therapeutics Inc (BEAM) has a Forward P/S ratio of 44.02. This means the market is valuing BEAM at $44.02 for every dollar of expected revenue over the next 12 months.